Jim Simons Beyond Spring Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.89 - $1.39 $99,319 - $155,117	-111,595 Reduced 91.19%	10,776 $13,000
Q1 2023 May 12, 2023	BUY	$1.06 - $3.05 $129,713 - $373,231	122,371 New	122,371 $137,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $1.81 $207,720 - $354,693	-195,963 Reduced 53.4%	170,996 $169,000
Q2 2022 Aug 12, 2022	BUY	$1.13 - $2.66 $95,582 - $224,998	84,586 Added 29.96%	366,959 $528,000
Q1 2022 May 13, 2022	BUY	$1.68 - $5.01 $423,482 - $1.26 Million	252,073 Added 831.92%	282,373 $621,000

Q4 2021 Feb 11, 2022	BUY	$4.02 - $16.84 $121,805 - $510,252	30,300 New	30,300 $137,000
Q2 2021 Aug 13, 2021	SELL	$9.37 - $12.12 $1.16 Million - $1.5 Million	-123,800 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$10.61 - $15.77 $264,846 - $393,650	24,962 Added 25.26%	123,800 $1.37 Million
Q4 2020 Feb 10, 2021	BUY	$10.21 - $17.31 $567,063 - $961,397	55,540 Added 128.27%	98,838 $1.21 Million
Q3 2020 Nov 13, 2020	SELL	$9.99 - $16.13 $316,702 - $511,353	-31,702 Reduced 42.27%	43,298 $576,000
Q2 2020 Aug 13, 2020	BUY	$11.21 - $18.15 $840,750 - $1.36 Million	75,000 New	75,000 $1.13 Million

5.44M

30.3K

1.8K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $95.4M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.